All Stories

  1. Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity

    Article • Pediatric Obesity, September 2018, Wiley

    Craig Friesen, Dr Andrea Gaedigk

  2. Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver

    Article • Clinical Pharmacology & Therapeutics, July 2018, Wiley

    Dr Andrea Gaedigk

  3. Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics

    Article • The Journal of Clinical Pharmacology, February 2018, Wiley

    Dr Andrea Gaedigk

  4. Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder

    Article • Pharmacogenomics, January 2018, Future Medicine

    Dr Andrea Gaedigk

  5. The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP ) Allele Nomenclature Database

    Article • Clinical Pharmacology & Therapeutics, November 2017, Wiley

    Dr Andrea Gaedigk

  6. Variants in the CYP2B6 3′UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs

    Article • Clinical Pharmacology & Therapeutics, October 2017, Wiley

    Dr Andrea Gaedigk

  7. In vivo characterization of CYP2D6*12, *29 and *84 using dextromethorphan as a probe drug: a case report

    Article • Pharmacogenomics, April 2017, Future Medicine

    Dr Andrea Gaedigk

  8. Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study

    Article • Pharmacogenomics, April 2017, Future Medicine

    Dr Andrea Gaedigk

  9. CYP450 genotype and pharmacogenetic association studies: a critical appraisal

    Article • Pharmacogenomics, February 2016, Future Medicine

    Dr Andrea Gaedigk

  10. Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6

    Article • Human Mutation, December 2015, Wiley

    Dr Andrea Gaedigk

  11. Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation

    Article • Drug Metabolism and Disposition, November 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Andrea Gaedigk

  12. Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting

    Article • Clinical Pharmacology & Therapeutics, November 2015, Wiley

    Dr Andrea Gaedigk

  13. CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification

    Article • Journal of Molecular Diagnostics, November 2015, Elsevier

    Dr Andrea Gaedigk

  14. Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort

    Article • The Pharmacogenomics Journal, October 2015, Nature

    Dr Andrea Gaedigk

  15. Age-Related Changes in MicroRNA Expression and Pharmacogenes in Human Liver

    Article • Clinical Pharmacology & Therapeutics, July 2015, Wiley

    Dr Andrea Gaedigk

  16. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2D6andCYP2C19Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

    Article • Clinical Pharmacology & Therapeutics, June 2015, Wiley

    Dr Andrea Gaedigk

  17. SNP genotyping using TaqMan® technology: the CYP2D6*17 assay conundrum

    Article • Scientific Reports, March 2015, Nature

    Dr Andrea Gaedigk

  18. Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics

    Article • Pharmacogenomics, December 2014, Future Medicine

    Dr Andrea Gaedigk

  19. Resolution of a clinical AmpliChip CYP450 Test™ no call: discovery and characterization of novelCYP2D6*1haplotypes

    Article • Pharmacogenomics, July 2014, Future Medicine

    Dr Andrea Gaedigk

  20. CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects

    Article • Pharmacogenomics, June 2014, Future Medicine

    Dr Andrea Gaedigk

  21. Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population

    Article • Pediatric Nephrology, May 2014, Springer Science + Business Media

    Dr Andrea Gaedigk

  22. Population Pharmacokinetics of Oral Baclofen in Pediatric Patients with Cerebral Palsy

    Article • The Journal of Pediatrics, May 2014, Elsevier

    Dr Andrea Gaedigk

  23. Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization

    Article • Current Drug Metabolism, March 2014, Bentham Science Publishers

    Dr Andrea Gaedigk

  24. CYP2D6 and pharmacogenomics: where does future research need to focus? Part 1: technical aspects

    Article • Pharmacogenomics, March 2014, Future Medicine

    Dr Andrea Gaedigk

  25. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

    Article • Clinical Pharmacology & Therapeutics, January 2014, Nature

    Dr Andrea Gaedigk

  26. Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP450 Test® no-call in the clinical setting

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2014, De Gruyter

    Dr Andrea Gaedigk, Professor Ignacio Jesús Dávila

  27. Complexities ofCYP2D6gene analysis and interpretation

    Article • International Review of Psychiatry, October 2013, Taylor & Francis

    Dr Andrea Gaedigk

  28. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity

    Article • Human Molecular Genetics, August 2013, Oxford University Press (OUP)

    Dr Andrea Gaedigk

  29. Regulation of MicroRNA Expression by Rifampin in Human Hepatocytes

    Article • Drug Metabolism and Disposition, August 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Andrea Gaedigk

  30. Pharmacogenetics in American Indian populations

    Article • Pharmacogenetics and Genomics, August 2013, Wolters Kluwer Health

    Dr Andrea Gaedigk

  31. Polymorphisms in CYP2D6 may predict methamphetamine related heart failure

    Article • Journal of Toxicology Clinical Toxicology, July 2013, Taylor & Francis

    Dr Andrea Gaedigk

  32. High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6

    Article • Pharmacogenomics, June 2013, Future Medicine

    Dr Andrea Gaedigk

  33. Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants

    Article • Pharmacogenomics, February 2013, Future Medicine

    Dr Andrea Gaedigk

  34. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

    Article • Clinical Pharmacology & Therapeutics, January 2013, Nature

    Dr Andrea Gaedigk

  35. Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study

    Article • BMC Medical Genetics, January 2013, Springer Science + Business Media

    Dr Andrea Gaedigk

  36. CYP2D6 update

    Article • Pharmacogenetics and Genomics, September 2012, Wolters Kluwer Health

    Dr Andrea Gaedigk

  37. The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients

    Article • Neurobiology of Aging, September 2012, Elsevier

    Dr Andrea Gaedigk

  38. Defining Risk Factors for Red Man Syndrome in Children and Adults

    Article • The Pediatric Infectious Disease Journal, May 2012, Wolters Kluwer Health

    Dr Andrea Gaedigk

  39. In Silico and In Vitro Identification of MicroRNAs That Regulate Hepatic Nuclear Factor 4α Expression

    Article • Drug Metabolism and Disposition, January 2012, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Andrea Gaedigk

  40. CYP2D6,SULT1A1andUGT2B17copy number variation: quantitative detection by multiplex PCR

    Article • Pharmacogenomics, January 2012, Future Medicine

    Dr Andrea Gaedigk

  41. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype

    Article • Clinical Pharmacology & Therapeutics, December 2011, Nature

    Dr Andrea Gaedigk

  42. Detection and characterization of theCYP2D6*9x2gene duplication in two Spanish populations: resolution of AmpliChip CYP450 test no-calls

    Article • Pharmacogenomics, November 2011, Future Medicine

    Dr Andrea Gaedigk

  43. Genetic Transmission of Cytochrome P450 2D6 (CYP2D6) Ultrarapid Metabolism: Implications for Breastfeeding Women taking Codeine

    Article • Current Drug Safety, February 2011, Bentham Science Publishers

    Dr Andrea Gaedigk

  44. Relapse of depressive and anxiety symptoms, and quality-of-life in pregnant users and discontinued users of antidepressants: Results from the OTIS Antidepressants Study

    Article • Reproductive Toxicology, February 2011, Elsevier

    Dr Andrea Gaedigk

  45. Erratum to: Discovery of the nonfunctional CYP2D6*31 allele in Spanish, Puerto Rican, and US Hispanic populations

    Article • European Journal of Clinical Pharmacology, November 2010, Springer Science + Business Media

    Dr Andrea Gaedigk

  46. Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan

    Article • Clinical Pharmacology & Therapeutics, September 2010, Nature

    Dr Andrea Gaedigk

  47. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver

    Article • Genome Research, June 2010, Cold Spring Harbor Laboratory Press

    Dr Andrea Gaedigk

  48. Elucidation of CYP2D6 Genetic Diversity in a Unique African Population: Implications for the Future Application of Pharmacogenetics in the Xhosa Population

    Article • Annals of Human Genetics, May 2010, Wiley

    Dr Andrea Gaedigk

  49. Discovery of the nonfunctional CYP2D6*31 allele in Spanish, Puerto Rican, and US Hispanic populations

    Article • European Journal of Clinical Pharmacology, May 2010, Springer Science + Business Media

    Dr Andrea Gaedigk

  50. Impact of the CYP2C19*17 Allele on the Pharmacokinetics of Omeprazole and Pantoprazole in Children: Evidence for a Differential Effect

    Article • Drug Metabolism and Disposition, March 2010, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Andrea Gaedigk

  51. Variability in drug metabolizing enzyme activity in HIV-infected patients

    Article • European Journal of Clinical Pharmacology, January 2010, Springer Science + Business Media

    Dr Andrea Gaedigk

  52. CYP2D7–2D6hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction

    Article • Pharmacogenomics, January 2010, Future Medicine

    Dr Andrea Gaedigk

  53. UGT2B17 and SULT1A1 gene copy number variation (CNV) detection by LabChip microfluidic technology

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2010, De Gruyter

    Dr Andrea Gaedigk

  54. Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants

    Article • Frontiers in Pharmacology, January 2010, Frontiers

    Dr Andrea Gaedigk

  55. Maribavir Pharmacokinetics and the Effects of Multiple-Dose Maribavir on Cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults

    Article • February 2009, SciVee, Inc

    Dr Andrea Gaedigk

  56. Single-Dose Pharmacokinetics of Oral and Intravenous Pantoprazole in Children and Adolescents

    Article • The Journal of Clinical Pharmacology, November 2008, Wiley

    Dr Andrea Gaedigk

  57. Reduced Activities of Cytochrome P450 1A2 and Xanthine Oxidase in Children With Growth Hormone Deficiency

    Article • Clinical Pharmacology & Therapeutics, October 2008, Nature

    Dr Andrea Gaedigk

  58. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study

    Article • Genetics in Medicine, October 2008, Nature

    Dr Andrea Gaedigk

  59. Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual

    Article • European Journal of Clinical Pharmacology, September 2008, Springer Science + Business Media

    Dr Andrea Gaedigk

  60. Evaluation of a [13C]-Dextromethorphan Breath Test to Assess CYP2D6 Phenotype

    Article • The Journal of Clinical Pharmacology, September 2008, Wiley

    Dr Andrea Gaedigk

  61. Six-month, prospective, longitudinal, open-Label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement

    Article • Clinical Therapeutics, September 2008, Elsevier

    Dr Andrea Gaedigk

  62. Pharmacogenetics of Neonatal Opioid Toxicity Following Maternal Use of Codeine During Breastfeeding: A Case–Control Study

    Article • Clinical Pharmacology & Therapeutics, August 2008, Nature

    Dr Andrea Gaedigk

  63. Molecular Therapeutics: 21st Century Medicine

    Article • Clinical Pharmacology & Therapeutics, July 2008, Nature

    Dr Andrea Gaedigk

  64. Interindividual variability in acetaminophen sulfation by human fetal liver: Implications for pharmacogenetic investigations of drug-induced birth defects

    Article • Birth Defects Research Part A Clinical and Molecular Teratology, March 2008, Wiley

    Dr Andrea Gaedigk

  65. The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements

    Article • European Journal of Clinical Pharmacology, January 2008, Springer Science + Business Media

    Dr Andrea Gaedigk

  66. The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype

    Article • Clinical Pharmacology & Therapeutics, October 2007, Nature

    Dr Andrea Gaedigk

  67. Multilocus Genotyping Identifies Infections by Multiple Strains of Trichophyton tonsurans

    Article • Journal of Clinical Microbiology, April 2007, ASM Journals

    Dr Andrea Gaedigk

  68. Effect of Arylamine Acetyltransferase Nat3 Gene Knockout on N-Acetylation in the Mouse

    Article • Drug Metabolism and Disposition, April 2007, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Andrea Gaedigk

  69. Identification and Characterization of CYP2D6*56B, an Allele Associated with the Poor Metabolizer Phenotype

    Article • Clinical Pharmacology & Therapeutics, March 2007, Nature

    Dr Andrea Gaedigk

  70. Ontogeny of Dextromethorphan O- and N-demethylation in the First Year of Life

    Article • Clinical Pharmacology & Therapeutics, February 2007, Nature

    Dr Andrea Gaedigk

  71. Cytochrome P4502D6 (CYP2D6) Gene Locus Heterogeneity: Characterization of Gene Duplication Events

    Article • Clinical Pharmacology & Therapeutics, February 2007, Nature

    Dr Andrea Gaedigk

  72. Tracking Trichophyton tonsurans Through a Large Urban Child Care Center: Defining Infection Prevalence and Transmission Patterns by Molecular Strain Typing

    Article • PEDIATRICS, December 2006, American Academy of Pediatrics (AAP)

    Dr Andrea Gaedigk

  73. Reply

    Article • Clinical Pharmacology & Therapeutics, November 2006, Nature

    Dr Andrea Gaedigk

  74. Maternal Codeine is Not Safe for all Breast-Fed Infants

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, November 2006, SAGE Publications

    Dr Andrea Gaedigk

  75. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother

    Article • The Lancet, August 2006, Elsevier

    Dr Andrea Gaedigk

  76. Variability of CYP2J2 Expression in Human Fetal Tissues

    Article • Journal of Pharmacology and Experimental Therapeutics, July 2006, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Andrea Gaedigk

  77. Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin

    Article • European Journal of Clinical Pharmacology, April 2006, Springer Science + Business Media

    Dr Andrea Gaedigk

  78. Maribavir Pharmacokinetics and the Effects of Multiple-Dose Maribavir on Cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults

    Article • Antimicrobial Agents and Chemotherapy, April 2006, ASM Journals

    Dr Andrea Gaedigk

  79. PIII-32Characterization of CYP2D7 expression: Does a CYP2D7-derived functional gene product exist?

    Article • Clinical Pharmacology & Therapeutics, February 2006, Nature

    Dr Andrea Gaedigk

  80. OIV-B-2Chronic intermittent nocturnal hypoxemia alters activities of hepatic cytochrome P4501A2 (CYP1A2), N-acetyltransferase 2 (NAT2) and xanthine oxidase (XO) in children with obstructive sleep apnea (OSA)

    Article • Clinical Pharmacology & Therapeutics, February 2006, Nature

    Dr Andrea Gaedigk

  81. LBOVI-B-4Recombinant human growth hormone (rhGH) has no effect on activities of hepatic cytochrome P4501A2 (CYP1A2), N-acetyltransferase 2 (NAT2), xanthine oxidase (XO) or cytochrome P4502D6 in children with idiopathic growth hormone (GH) deficiency

    Article • Clinical Pharmacology & Therapeutics, February 2006, Nature

    Dr Andrea Gaedigk

  82. CYP2D6*36GENE ARRANGEMENTS WITHIN THECYP2D6LOCUS: ASSOCIATION OFCYP2D6*36WITH POOR METABOLIZER STATUS

    Article • Drug Metabolism and Disposition, January 2006, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Andrea Gaedigk

  83. Effect of a Triphasic Oral Contraceptive on Drug-Metabolizing Enzyme Activity as Measured by the Validated Cooperstown 5+1 Cocktail

    Article • The Journal of Clinical Pharmacology, December 2005, Wiley

    Dr Andrea Gaedigk

  84. Multiple Dose Pharmacokinetics of Paroxetine in Children and Adolescents with Major Depressive Disorder or Obsessive–Compulsive Disorder

    Article • Neuropsychopharmacology, November 2005, Nature

    Dr Andrea Gaedigk

  85. Identification of CYP2D6 impaired functional alleles in Mexican Americans

    Article • European Journal of Clinical Pharmacology, November 2005, Springer Science + Business Media

    Dr Andrea Gaedigk

  86. CYP2D7 splice variants in human liver and brain: Does CYP2D7 encode functional protein?

    Article • Biochemical and Biophysical Research Communications, November 2005, Elsevier

    Dr Andrea Gaedigk

  87. Characterization of the ALP1 Gene Locus of Trichophyton tonsurans

    Article • Mycopathologia, November 2005, Springer Science + Business Media

    Dr Andrea Gaedigk

  88. Limited Association of the 2988g>a Single Nucleotide Polymorphism with CYP2D6*41 in Black Subjects

    Article • Clinical Pharmacology & Therapeutics, March 2005, Nature

    Dr Andrea Gaedigk

  89. Effect of the anti-cytomegalovirus (CMV) drug maribavir (MB) on the activities of cytochrome p450 (CYP) 1A2, 2C9, 2C19, 2D6, 3A, N-ACETYLTRANSFERASE-2 (NAT-2), and xanthine oxidase (XO) as assessed by the cooperstown 5+1 drug cocktail

    Article • Clinical Pharmacology & Therapeutics, February 2005, Nature

    Dr Andrea Gaedigk

  90. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans

    Article • The Pharmacogenomics Journal, January 2005, Nature

    Dr Andrea Gaedigk, Dr Peter K Rogan

  91. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans

    Article • The Pharmacogenomics Journal, January 2005, Nature

    Dr Andrea Gaedigk, Dr Peter K Rogan

  92. Pharmacokinetics and genotypes do not predict metoprolol adverse events or efficacy in hypertension

    Article • Clinical Pharmacology & Therapeutics, December 2004, Nature

    Dr Andrea Gaedigk

  93. Lack of Weight-Based Dose Dependency and Intraindividual Variability of Omeprazole for CYP2C19 Phenotyping

    Article • The Journal of Clinical Pharmacology, September 2004, Wiley

    Dr Andrea Gaedigk

  94. Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction Through Cytochrome P-450 Induction

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, August 2004, Wolters Kluwer Health

    Dr Andrea Gaedigk

  95. Limited Sampling Strategy of S-Warfarin Concentrations, but Not Warfarin S/R Ratios, Accurately Predicts S-Warfarin AUC during Baseline and Inhibition in CYP2C9 Extensive Metabolizers

    Article • The Journal of Clinical Pharmacology, June 2004, Wiley

    Dr Andrea Gaedigk

  96. Extensive alternative splicing of cytochrome P4502D6 (CYP2D6) mRNA: explanation for variability among subjects with identical genotypes?

    Article • Clinical Pharmacology & Therapeutics, February 2004, Nature

    Dr Andrea Gaedigk

  97. Genetic Heterogeneity in the rRNA Gene Locus of Trichophyton tonsurans

    Article • Journal of Clinical Microbiology, December 2003, ASM Journals

    Dr Andrea Gaedigk

  98. Omeprazole Disposition in Children following Single-Dose Administration

    Article • The Journal of Clinical Pharmacology, August 2003, Wiley

    Dr Andrea Gaedigk

  99. Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D6*42, in African American subjects

    Article • Clinical Pharmacology & Therapeutics, June 2003, Nature

    Dr Andrea Gaedigk

  100. CYP2D6 Poor Metabolizer Status Can Be Ruled Out by a Single Genotyping Assay for the -1584G Promoter Polymorphism

    Article • Clinical Chemistry, June 2003, AACC

    Dr Andrea Gaedigk

  101. Evaluation of Inhibitory Effects of Metoclopramide (MET) on CYP2D6 Activity in Infants

    Article • Clinical Pharmacology & Therapeutics, February 2003, Nature

    Dr Andrea Gaedigk

  102. Characterization of an African American (AA) subject carrying two novel functional CYP2D6 alleles.

    Article • Clinical Pharmacology & Therapeutics, February 2003, Nature

    Dr Andrea Gaedigk

  103. Effect of cigarette smoking on CYP2C9 activity.

    Article • Clinical Pharmacology & Therapeutics, February 2003, Nature

    Dr Andrea Gaedigk

  104. Pantoprazole Disposition in Pediatrics

    Article • Clinical Pharmacology & Therapeutics, February 2003, Nature

    Dr Andrea Gaedigk

  105. Allelic variation of the pregnane X receptor (PXR) and CYP3A4 activity

    Article • Clinical Pharmacology & Therapeutics, February 2003, Nature

    Dr Andrea Gaedigk

  106. Variability in thiopurine methyltransferase (TPMT) and outcome in pediatric renal transplant patients.

    Article • Clinical Pharmacology & Therapeutics, February 2003, Nature

    Dr Andrea Gaedigk

  107. Effect of oral contraceptives (OCS) on drug metabolizing enzymes (DMES) as measured by the validated cooperstown 5+1 cocktail (5+1).

    Article • Clinical Pharmacology & Therapeutics, February 2003, Nature

    Dr Andrea Gaedigk

  108. Use of limited sampling strategy (LSS) of S-warfarin (S-W) concentrations or warfarin (W) S/R ratios as a biomarker for CYP2C9 activity.

    Article • Clinical Pharmacology & Therapeutics, February 2003, Nature

    Dr Andrea Gaedigk

  109. Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker

    Article • Clinical Pharmacology & Therapeutics, August 2002, Springer Science + Business Media

    Dr Andrea Gaedigk

  110. CYP2D6 Inhibition by Selective Serotonin Reuptake Inhibitors: Analysis of Achievable Steady-State Plasma Concentrations and the Effect of Ultrarapid Metabolism at CYP2D6

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, August 2002, Wiley

    Dr Andrea Gaedigk

  111. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans*

    Article • Clinical Pharmacology & Therapeutics, July 2002, Nature

    Dr Andrea Gaedigk

  112. Concordance between Tramadol and Dextromethorphan Parent/Metabolite Ratios: The Influence of CYP2D6 and Non-CYP2D6 Pathways on Biotransformation

    Article • The Journal of Clinical Pharmacology, January 2002, Wiley

    Dr Andrea Gaedigk

  113. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations

    Article • Canadian Journal of Physiology and Pharmacology, October 2001, Canadian Science Publishing

    Dr Andrea Gaedigk

  114. Effects of Oral Vitamin K on S- and R-Warfarin Pharmacokinetics and Pharmacodynamics: Enhanced Safety of Warfarin as a CYP2C9 Probe

    Article • The Journal of Clinical Pharmacology, July 2001, Wiley

    Dr Andrea Gaedigk

  115. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations

    Article • Canadian Journal of Physiology and Pharmacology, January 2001, Canadian Science Publishing

    Dr Andrea Gaedigk

  116. Interethnic differences of drug-metabolizing enzymes

    Article • International Journal of Clinical Pharmacology and Therapeutics, February 2000, Dustri-Verlgag Dr. Karl Feistle

    Dr Andrea Gaedigk

  117. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data

    Article • Pharmacogenetics and Genomics, December 1999, Wolters Kluwer Health

    Dr Andrea Gaedigk

  118. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data

    Article • Pharmacogenetics, December 1999, Wolters Kluwer Health

    Dr Andrea Gaedigk

  119. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping

    Article • Clinical Pharmacology & Therapeutics, November 1999, Nature

    Dr Andrea Gaedigk

  120. Crystal structure of human catecholamine sulfotransferase 1 1Edited by R. Huber

    Article • Journal of Molecular Biology, October 1999, Elsevier

    Dr Andrea Gaedigk

  121. Accuracy of cytochrome P4502D6 (CYP2D6): Phenotype assignment from genotyping data1

    Article • Clinical Pharmacology & Therapeutics, February 1999, Nature

    Dr Andrea Gaedigk

  122. Acquistion of functional CYP2D6 activity in the first year of life1

    Article • Clinical Pharmacology & Therapeutics, February 1999, Nature

    Dr Andrea Gaedigk

  123. Absence of dose-dependency for CYP2D6 phenotyping (PT) with dextromethorphan (DM)

    Article • Clinical Pharmacology & Therapeutics, February 1999, Nature

    Dr Andrea Gaedigk

  124. CYP2D6 allele frequencies in African Americans: Phenotype concordance with dextromethorphan (DM)

    Article • Clinical Pharmacology & Therapeutics, February 1999, Nature

    Dr Andrea Gaedigk

  125. CYP2C9 genotype and ibuprofen (IBU) pharmacokinetics (PK) in cystic fibrosis (CF)1

    Article • Clinical Pharmacology & Therapeutics, February 1999, Nature

    Dr Andrea Gaedigk

  126. Determinants of warfarin S:R ratio in orthopedic surgery (OS) patients

    Article • Clinical Pharmacology & Therapeutics, February 1999, Nature

    Dr Andrea Gaedigk

  127. Structural characterization of human aryl sulphotransferases

    Article • Biochemical Journal, January 1999, Portland Press Ltd.

    Dr Andrea Gaedigk

  128. Structural characterization of human aryl sulphotransferases

    Article • Biochemical Journal, January 1999, Portland Press Ltd.

    Dr Andrea Gaedigk

  129. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping

    Article • Pharmacogenetics, October 1998, Wolters Kluwer Health

    Dr Andrea Gaedigk

  130. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians

    Article • Pharmacogenetics, August 1998, Wolters Kluwer Health

    Dr Andrea Gaedigk

  131. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations

    Article • Pharmacogenetics, August 1998, Wolters Kluwer Health

    Dr Andrea Gaedigk

  132. Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions

    Article • Pharmacogenetics, June 1998, Wolters Kluwer Health

    Dr Andrea Gaedigk

  133. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype

    Article • Journal of Chromatography B Biomedical Sciences and Applications, June 1998, Elsevier

    Dr Andrea Gaedigk

  134. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population

    Article • Pharmacogenetics, February 1998, Wolters Kluwer Health

    Dr Andrea Gaedigk

  135. Bacterial expression of two human aryl sulfotransferases

    Article • Chemico-Biological Interactions, February 1998, Elsevier

    Dr Andrea Gaedigk

  136. Novel sulfotransferases cloned by RT-PCR: real proteins or PCR artifacts?

    Article • Chemico-Biological Interactions, February 1998, Elsevier

    Dr Andrea Gaedigk

  137. Tissue-Specific Expression and Alternative Splicing of Human Microsomal Epoxide Hydrolase

    Article • DNA and Cell Biology, November 1997, Mary Ann Liebert Inc

    Dr Andrea Gaedigk

  138. Human acetyltransferase polymorphisms

    Article • Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, May 1997, Elsevier

    Dr Andrea Gaedigk

  139. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: Functional and localization studies

    Article • Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, May 1997, Elsevier

    Dr Andrea Gaedigk

  140. Cloning, Structural Organization, and Chromosomal Mapping of the Human Phenol SulfotransferaseSTP2Gene

    Article • Genomics, March 1997, Elsevier

    Dr Andrea Gaedigk

  141. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity

    Article • Biochemical Pharmacology, October 1995, Elsevier

    Dr Andrea Gaedigk

  142. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions

    Article • Pharmacogenetics, June 1994, Wolters Kluwer Health

    Dr Andrea Gaedigk

  143. Debrisoquine/Sparteine Hydroxylation Genotype and Phenotype: Analysis of Common Mutations and Alleles of CYP2D6 in a European Population

    Article • DNA and Cell Biology, October 1991, Mary Ann Liebert Inc

    Dr Andrea Gaedigk

  144. Identification of the primary gene defect at the cytochrome P450 CYP2D locus

    Article • Nature, October 1990, Nature

    Dr Andrea Gaedigk

  145. Faculty of 1000 evaluation for Children, biobanks and the scope of parental consent.

    Article • Faculty of 1000, Ltd.

    Dr Andrea Gaedigk

  146. Faculty of 1000 evaluation for Clinical assessment incorporating a personal genome.

    Article • Faculty of 1000, Ltd.

    Dr Andrea Gaedigk

  147. Faculty of 1000 evaluation for Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.

    Article • Faculty of 1000, Ltd.

    Dr Andrea Gaedigk

  148. Faculty of 1000 evaluation for The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.

    Article • Faculty of 1000, Ltd.

    Dr Andrea Gaedigk

  149. Faculty of 1000 evaluation for A genome-wide association study of metabolic traits in human urine.

    Article • Faculty of 1000, Ltd.

    Dr Andrea Gaedigk

  150. Faculty of 1000 evaluation for Functional characterization of liver enhancers that regulate drug-associated transporters.

    Article • Faculty of 1000, Ltd.

    Dr Andrea Gaedigk

  151. Faculty of 1000 evaluation for Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.

    Article • Faculty of 1000, Ltd.

    Dr Andrea Gaedigk

  152. Faculty of 1000 evaluation for A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury.

    Article • Faculty of 1000, Ltd.

    Dr Andrea Gaedigk

  153. Faculty of 1000 evaluation for Predicting adverse drug reactions using publicly available PubChem BioAssay data.

    Article • Faculty of 1000, Ltd.

    Dr Andrea Gaedigk

  154. Faculty of 1000 evaluation for [CONFERENCE POSTER]: Intestinal CYP3A4 and midazolam disposition in vivo show seasonal variation and associate with VDR polymorphisms.

    Article • Faculty of 1000, Ltd.

    Dr Andrea Gaedigk

  155. Faculty of 1000 evaluation for Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls.

    Article • Faculty of 1000, Ltd.

    Dr Andrea Gaedigk

  156. Faculty of 1000 evaluation for [CONFERENCE POSTER]: Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients.

    Article • Faculty of 1000, Ltd.

    Dr Andrea Gaedigk